NeuroMetrix (NASDAQ:NURO) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report issued on Saturday morning. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Price Performance

Shares of NURO opened at $4.38 on Friday. NeuroMetrix has a 1-year low of $2.66 and a 1-year high of $4.73. The stock has a market cap of $8.94 million, a price-to-earnings ratio of -0.96 and a beta of 2.18. The firm has a 50 day simple moving average of $4.06 and a 200-day simple moving average of $3.93.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.